Aurinia Pharmaceuticals Inc.
Health
Performance
8.2
Risk
Sell
Buy
Curious about the Scores? Learn more.

Aurinia Pharmaceuticals Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

16.01.2026
Red alert. Risk levels out of control.
11.01.2026
Slowing down. Might be a breather – or a shift.
09.01.2026
Losing steam. Solid pieces remain, but cracks are showing.
20.08.2025
Health’s picking up. Numbers look cleaner, cash flow tighter.

Aurinia Pharmaceuticals Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Aurinia Pharmaceuticals Inc. do? Business model and key facts

Get the full picture of Aurinia Pharmaceuticals Inc.: what it builds, where it operates, and how it makes money.

Aurinia Pharmaceuticals Inc. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 130

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

shop
Company facts
Peter S. Greenleaf
CEO
130
Employees worldwide
shop
Performance
93.37%
Last 12 months
11.72%
Last 5 years
shop
Growth
$235,13M
Revenue year
$5,75M
Net income
shop
Valuation
$1,96B
Market Cap
223.34
Price/Earnings Ratio

Stocks related to Aurinia Pharmaceuticals Inc.

Selected based on industry alignment and relative market positioning.

LEGN
Legend Biotech Corporation
22.11
-5.03%
7.6
Sell
Buy
Legend Biotech Corporation
ZLAB
Zai Lab Limited
18.82
-4.03%
8.8
Sell
Buy
Zai Lab Limited
HRMY
Harmony Biosciences Holdings, Inc.
36.41
+1.03%
6.3
Sell
Buy
Harmony Biosciences Holdings, Inc.
VCEL
Vericel Corporation
38.57
+3.32%
6.9
Sell
Buy
Vericel Corporation
MAZE
Maze Therapeutics, Inc.
39.81
-3.16%
8.6
Sell
Buy
Maze Therapeutics, Inc.

Aurinia Pharmaceuticals Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.